Armata Pharmaceuticals, Inc.
ARMP
$2.47
$0.041.65%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.87M | 4.70M | 5.17M | 5.47M | 3.72M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.87M | 4.70M | 5.17M | 5.47M | 3.72M |
| Cost of Revenue | 39.65M | 39.80M | 42.39M | 41.48M | 41.31M |
| Gross Profit | -32.78M | -35.10M | -37.22M | -36.02M | -37.59M |
| SG&A Expenses | 12.44M | 13.26M | 13.18M | 13.04M | 13.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.20M | 45.10M | 47.61M | 46.94M | 45.78M |
| Operating Income | -35.33M | -40.40M | -42.44M | -41.48M | -42.06M |
| Income Before Tax | -25.71M | -426.00K | -18.92M | -41.36M | -67.04M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.71 | -0.43 | -18.92 | -41.36 | -67.04 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.71M | -426.00K | -18.92M | -41.36M | -67.04M |
| EBIT | -35.33M | -40.40M | -42.44M | -41.48M | -42.06M |
| EBITDA | -33.89M | -39.02M | -41.11M | -40.24M | -40.91M |
| EPS Basic | -0.71 | -0.01 | -0.52 | -1.15 | -1.86 |
| Normalized Basic EPS | -0.84 | -0.90 | -0.91 | -0.86 | -0.85 |
| EPS Diluted | -1.32 | -1.12 | -1.62 | -1.64 | -2.35 |
| Normalized Diluted EPS | -0.66 | -0.64 | -0.72 | -0.77 | -0.75 |
| Average Basic Shares Outstanding | 144.74M | 144.70M | 144.64M | 144.56M | 144.47M |
| Average Diluted Shares Outstanding | 190.93M | 212.99M | 189.63M | 166.65M | 166.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |